Overview
Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients
Status:
Completed
Completed
Trial end date:
2013-12-01
2013-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
- To assess the safety and tolerability of repeat dose topical administration of MRZ-99030 Ophthalmic Solution with ascending doses in healthy subjects (stage 1) and glaucoma subjects (stage 2). - To assess plasma pharmacokinetics and urine concentration of MRZ- 99030 and its metabolite MRZ-9499 after single and repeat dose topical administration of MRZ-99030 Ophthalmic Solution.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Merz Pharmaceuticals GmbHTreatments:
Ophthalmic Solutions
Tetrahydrozoline
Criteria
Inclusion Criteria:For stage 1:
- Healthy volunteers
For stage 2:
- Glaucoma patients
Exclusion Criteria:
For stage 2:
- Any relevant eye disease other than glaucoma